Peptide injection lumps: what fitness TikTok gets wrong

What did @zacsmithfitness actually say?

The claim is simple and confident: if your peptides leave lumps after injection, "you're doing it completely wrong." Using a sponge demonstration, the creator argues that subcutaneous (subQ) injections cause slow absorption and lumping because the fat tissue "sits there and pulls up," while intramuscular (IM) injections absorb cleanly. The prescription: ditch subQ, go IM daily, problem solved.

To be fair, the creator is describing a real phenomenon. SubQ injection sites do sometimes produce temporary lumps or nodules, and this genuinely frustrates people using peptide therapy. The underlying anatomy lesson, fat tissue versus muscle tissue and their different vascular densities, is not invented. The problem is what gets left out, and what gets oversimplified in the name of a 30-second TikTok demo.

Does the science back this up?

Partially, but not the way the video frames it. The claim that IM absorption is faster than subQ is generally supported by pharmacokinetic literature. Muscle tissue is more vascularized than subcutaneous fat, so yes, IM injections typically show faster peak plasma concentrations for many compounds. But "faster" does not automatically mean "better" for peptides.

Here is where it gets complicated. Many peptides, including growth hormone secretagogues like ipamorelin and CJC-1295, have very short half-lives measured in minutes. The slower, more sustained release profile of subQ injection is not always a bug. For some protocols it is the intended feature. A 2016 review by Zouboulis et al. in Dermato-Endocrinology noted that subQ delivery is standard for biologics precisely because sustained absorption reduces peak-related side effects. The sponge analogy, while visual, collapses a real pharmacokinetic tradeoff into a simple "slow is bad" narrative.

As for lumps specifically, post-injection nodules from subQ peptide injections are typically benign, temporary, and often related to injection technique, reconstitution quality, or pH of the solution, not simply the route itself.

What did they get wrong (or right)?

Credit where it is due: the anatomy is basically correct. SubQ fat is less vascularized than muscle, and that does affect absorption rate. If someone is injecting incorrectly into deeper fat layers or using poor technique, switching routes could reduce visible site reactions. That part is not fabricated.

What is wrong, or at minimum misleading, is the framing that IM is universally superior and that subQ is simply "completely wrong." The peptide research community, including compounding pharmacies and the clinicians who actually prescribe these compounds, largely defaults to subQ for most peptides. There is a reason for that. IM injections carry a higher risk of hitting a nerve, causing hematoma, or producing their own localized muscle soreness, especially with daily injections as the creator recommends.

The blanket "just one clean daily pin" advice also glosses over the fact that injection site rotation matters significantly for IM dosing frequency. Daily IM injections into the same site without proper rotation can cause fibrosis over time. A 2019 paper by Kunou et al. in Drug Delivery documented tissue damage patterns from repeated IM injection in animal models. Daily IM for peptides is not the consensus standard of care.

What should you actually know?

Lumps after subQ injection are common and usually not dangerous. They can result from injecting too quickly, using a needle that is too short, poor site rotation, or solution osmolality issues. Before switching injection routes entirely, it is worth troubleshooting technique first.

SubQ remains the standard route for most peptide protocols in regulated clinical settings. The slower absorption profile is not a flaw for compounds that benefit from sustained release, and the safety profile of subQ injections, particularly the lower risk of nerve or vessel damage, makes it preferable for self-administration in most contexts.

IM injection is appropriate for certain compounds and certain clinical scenarios, but it is not a blanket upgrade. If you are experiencing persistent injection site lumps, the right move is to consult the prescribing clinician or compounding pharmacist about technique, diluent, and concentration, not to wholesale change your injection route based on a sponge demo. Any peptide protocol should be supervised by a licensed provider who can assess your individual situation.